Clinical Trials Logo

Giant Cell Tumors clinical trials

View clinical trials related to Giant Cell Tumors.

Filter by:

NCT ID: NCT04952818 Completed - Spinal Tumor Clinical Trials

The Value of Preoperative Diagnosis and Prognostic Prediction Based on Radiomics of Giant Cell Tumor of Spine

Start date: January 1, 2020
Phase:
Study type: Observational

1. Exploit CT (plain scan), enhanced CT and fMRI based radiomic biomarkers, explore their correlation with the prognostic molecular markers of spinal GCTB(p53/vegf/rank/rankl…), and help accurate diagnosis of GCTB. 2. Exploring a new method of preoperative risk stratification for spinal GCTB, and establishing radiomic model combined with clinical features. Exploring the GCTB biological behavior prediction model and the prognosis prediction of GCTB.

NCT ID: NCT04938180 Active, not recruiting - Clinical trials for Tenosynovial Giant Cell Tumor

A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients

Start date: September 16, 2021
Phase: Phase 2
Study type: Interventional

The purpose of this Phase 2, open-label, multiple-dose, dose-escalation study is to evaluate intravenous AMB-05X in the treatment of patients with TGCT.

NCT ID: NCT04731675 Active, not recruiting - Clinical trials for Tenosynovial Giant Cell Tumor

An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee

Start date: May 25, 2021
Phase: Phase 2
Study type: Interventional

AMB-051-01 is a multicenter study with an adaptive design that will enroll approximately 12 subjects with TGCT of the knee for 12 weeks of multiple-dose, open-label treatment with AMB-05X.

NCT ID: NCT04703322 Recruiting - Clinical trials for Tenosynovial Giant Cell Tumor

A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan

Start date: March 15, 2021
Phase: Phase 2
Study type: Interventional

This phase 2, multicenter, two-part, open-label, single-arm study will be conducted in Japan and will evaluate the safety, tolerability, pharmacokinetics (PK), and efficacy of pexidartinib in adult participants with symptomatic tenosynovial giant cell tumor (TGCT) associated with severe morbidity or functional limitation and not amenable to improvement with surgery.

NCT ID: NCT04635111 Recruiting - Clinical trials for Tenosynovial Giant Cell Tumor

A Long-term Study Evaluating Hepatotoxicity Associated With TURALIO™ (Pexidartinib) Treatment

Start date: January 7, 2021
Phase:
Study type: Observational [Patient Registry]

A study to evaluate the long-term risk of hepatic failure with TURALIO™ (pexidartinib) and the mechanism of liver injury based upon liver biopsy information among patients who received or are receiving TURALIO™ (pexidartinib) and experience hepatotoxicity.

NCT ID: NCT04586660 Recruiting - Clinical trials for Giant Cell Tumor of Bone

Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone

Start date: August 17, 2023
Phase: Phase 4
Study type: Interventional

The study aims to evaluate the efficacy of XGEVA® in Chinese participants with giant cell tumor of bone (GCTB).

NCT ID: NCT04526704 Completed - Clinical trials for Tenosynovial Giant Cell Tumor

Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib

PLX3397
Start date: October 20, 2020
Phase: Phase 4
Study type: Interventional

This study is designed to evaluate the discontinuation/re-treatment of pexidartinib therapy in previously treated participants with tenosynovial giant cell tumor (TGCT).

NCT ID: NCT04488822 Active, not recruiting - Clinical trials for Tenosynovial Giant Cell Tumor

A Study of the Efficacy and Safety of Pexidartinib in Adult Subjects With TGCT

PLX3397
Start date: September 25, 2020
Phase: Phase 3
Study type: Interventional

This study will assess pexidartinib in adult participants with symptomatic TGCT that is associated with severe morbidity or functional limitations and not amendable to improvement with surgery.

NCT ID: NCT04255576 Active, not recruiting - Clinical trials for Giant Cell Tumor of Bone

Efficacy and Safety of JMT103 in Patients With Giant Cell Tumor of Bone

Start date: October 10, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a phase Ib/II, multicenter, single-arm, open-label study to evaluate the efficacy and safety of JMT103 in patients with surgically unsalvageable or refractory giant cell tumor of bone (GCTB).

NCT ID: NCT04192344 Recruiting - Neoplasms Clinical Trials

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor

Start date: January 20, 2020
Phase: Phase 1
Study type: Interventional

This is an open-label phase 1 study to determine the safety and tolebility of oral ABSK021 in patients with advanced solid tumor as well as the Recommended Phase 2 dose (RP2D) of oral ABSK021. Preliminary antitumor activity will also be assessed.